Raymond James analyst Dane Leone upgraded Relay Therapeutics to Strong Buy from Outperform with a $29 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RLAY:
- Relay Therapeutics to Participate in Two Upcoming Investor Conferences
- Relay Therapeutics Plunges on Latest Cancer Data
- Oppenheimer ‘not surprised’ by Relay plunge, but thinks 2608 ‘looks like a drug’
- Relay Therapeutics to host conference call
- Relay Therapeutics says RLY-2608 selectively targets multiple PI3Ka mutations